Award winning executive search to the private, and investor backed health, care, and life sciences sectors

Health Tech Round Table: A discussion around the challenges and opportunities within HealthTech domestically and globally

December 4, 2024

The forward-thinking CFO: Leadership in the ever-changing Healthcare sector.

October 16, 2024

What is the next big innovation coming to the Life Sciences sector?

Trusted executive search partner to the investment community delivering outstanding leaders for the healthcare and life sciences sectors

Mandates delivered to date

0 %

Delivery rate of all retained mandates

0 %

C-suite appointments are women

0 +

Sub-sectors in healthcare and life sciences supported

Healthcare news, data and analysis
Via Investors in Healthcare

TSE-listed Topcon Corporation, a Japanese technology company specializing in optical, surveying, and precision positioning equipment, as well as healthcare and smart infrastructure solutions. is launching a MBO led by Topcon president and […]

Japan: Topcon accelerating growth through MBO with KKR and JIC Capital

March 28, 2025

Buy Out Healthcare News Ophthalmology Public Equity

Novo Holdings has had a busy week, co-leading and participating in major financing rounds across diverse areas of the life sciences industry. From cardiovascular devices and autoimmune disease treatments to […]

This week at Novo Holdings: Backing breakthrough life science innovation

March 28, 2025

Life Sciences News Pharma Venture 415 Capital

Euronext and Nasdaq-listed global healthcare company, Sanofi, and US-based Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi will acquire DR-0201, a targeted […]

France: Sanofi to pay up to US$1.3bn for Dren Bio’s bispecific myeloid cell engager

March 27, 2025

Manufacturing – Specialty Pharma News Pharma Dren Bio France

Direct lender, Colesco, has provided financing to Netherlands-based Ace Pharmaceuticals, an independent pharmaceutical company specialising in niche medical need products. The unitranche loan provided by Colesco will be used to […]

The Netherlands: Colesco provides unitranche loan to Ace Pharma

March 27, 2025

Debt Manufacturing – Generics News Pharma Services – CRO/CMO/CDMO

Kelso Pharma, the Apposite Capital-backed specialty pharma, has secured over £140m of acquisition funding, a proportion of which was used by Kelso in its acquisition of Alturix in February. The […]

UK: Kelso secures acquisition funding as it pursues growth across UK and Europe

March 27, 2025

Articles Debt News People Pharma

Shares of Asker Healthcare Group, a provider of medical products and solutions in Europe, have begun trading on Nasdaq Stockholm following its IPO, rising over 17% in early trading to […]

Sweden: Asker Healthcare shares rise in price on first day of trading

March 27, 2025

Life Sciences Medtech – Hospital Equipment Medtech – Medical Devices and Implants News Public Equity

THG has raised £90m (US$116m) from new and existing shareholders, including a £60m contribution from the firm’s founder and CEO Matthew Moulding. The equity contribution is comprised of £30m in new ordinary […]

UK: THG raises £90m with founder and CEO contributing £60m

March 26, 2025

Consumer Healthcare Cosmetic & Aesthetics Debt Healthcare News

The Carestone Group, a leading care home developer in Germany, aims to provide the real estate that gives people the freedom to live self-determined lives into old age. The company […]

IIH interview: ActivumSG’s Daniel Ahrendt discusses Carestone’s role in filling Germany’s senior living real estate supply gap

March 26, 2025

Articles

XRP Healthcare, an AI-driven healthcare and M&A platform, built on the XRPL, dedicated to consolidating and modernizing healthcare systems across emerging markets, starting in Africa, has announced it will IPO on […]

UAE: XRP Healthcare brings forward listing plans to Q3 2025

March 25, 2025

News Public Equity ARC Group UAE XRP Healthcare

Germany-based Amboss, a medical knowledge and learning platform, has secured €240m (US$260m) in a financing round to help expands its position as the leading co-pilot for physicians worldwide. The financing […]

Germany: Amboss secures €240m to fund investment in technology and new market segments

March 25, 2025

Education Healthcare News Venture AMBOSS

SIX-Swiss listed Alcon, the largest eye care device company in the world, is acquiring Nasdaq-listed Lensar, a global medical technology company focused on advanced laser solutions for the treatment of […]

Switzerland: Alcon agrees acquisition of Lensar for up to US$430m

March 25, 2025

Healthcare M&A News Ophthalmology Alcon

Augustine Therapeutics has completed a €77.7m (US$84.8m) Series A financing round co-led by Novo Holdings and Jeito Capital, supported by existing investors Asabys Partners, who led an initial €17.5m closing […]

Belgium: Augustine Therapeutics completes €77.7m Series A

March 24, 2025

News Pharma Venture AdBio partners Asabys Partners

Thena Capital, a UK-based early-stage medical technology investor, has launched its Fund I with a first close at £27m (US$35m) of its £50m target. The fund will invest across the […]

UK: Thena Capital launches Fund I with first close of £27m

March 21, 2025

Healthcare Life Sciences Medtech – Healthcare IT Mental Health News

France-based European healthcare-specialized investment firm Mérieux Equity Partners (MxEP) has acquired a majority stake in curea medical, a carve-out from McAirlaid’s. The investment aims to support curea’s growth and innovation […]

Germany: Mérieux Equity Partners acquires majority stake in curea medical

March 21, 2025

Debt Life Sciences M&A Medtech – Hospital Equipment Medtech – Medical Devices and Implants

Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, has completion a £14m (US$18m) Series C investment round co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture […]

UK: Brainomix completes Series C funding round as it accelerates into US

March 21, 2025

Life Sciences Medtech – Healthcare IT News Venture Boehringer Ingelheim Venture Fund (BIVF)

Paolo Pieri has left his role as CEO at Circle Health Group, the UK’s largest private hospital group. Karen Prins, currently COO at the firm, is stepping into the CEO […]

UK: Karen Prins steps into interim CEO role at Circle Health Group following departure of Paolo Pieri

March 20, 2025

Healthcare Hospitals and Clinics People Circle Health Group Karen Prins

Johan Löf, CEO and founder of Sweden-based medtech company Raysearch Laboratories has sold 2 million class B shares, corresponding to 5.8% of the company’s share capital, at SEK250 per share […]

Sweden: Raysearch founder raises SEK500m from sale of company shares

March 20, 2025

Life Sciences Medtech – Healthcare IT News Public Equity Baker & McKenzie

UK pharma, Pfizer, has received gross proceeds of approximately £2.5bn (US$3.3bn) from the sale of its entire remaining shareholding in British healthcare company, Haleon, of approximately 662 million ordinary shares, representing […]

UK: Pfizer raises £2.5bn from disposal of last holding in Haleon

March 20, 2025

Consumer Healthcare Healthcare News Public Equity Barclays

British Patient Capital, a commercial subsidiary of the British Business Bank, has made a £25m (US$32m) commitment to the Dementia Discovery Fund 2 (DDF-2), managed by SV Health Investors. Including […]

UK: SV Health Investors’ Dementia Discovery Fund 2 (DDF-2) secures £25m commitment from British Patient Capital

March 20, 2025

Healthcare Mental Health News Venture British Patient Capital

Maxion Therapeutics, a biotech company developing antibody-based ‘KnotBody’ drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, has raised US$72m (£58m) in a Series A financing led by […]

UK: Maxion Therapeutics raises US$72m in Series A financing

March 19, 2025

Manufacturing – Specialty Pharma News Pharma Venture Arndt Schottelius

Diaverum, a Sweden-born, multinational healthcare organisation providing life-enhancing renal care to patients with chronic kidney disease, is expanding in Germany with the acquisition of two new clinics, bringing its current […]

Germany: Diaverum expands in Germany with acquisition of two new clinics

March 19, 2025

Healthcare Hospitals and Clinics M&A News Diaverum

Healthcare Holding Schweiz, a distributor of medical devices and services across the Swiss healthcare landscape managed by multi-family investor Winterberg Advisory, has acquired Effectum CH-Rep. Through this acquisition, Healthcare Holding Schweiz strengthens its position […]

Switzerland: Healthcare Holding Schweiz adds Effectum CH-Rep to growing portfolio

March 19, 2025

Buy Out Life Sciences M&A Medtech – Hospital Equipment Medtech – Medical Devices and Implants

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a Belgium-based biotech company pioneering in vivo cell therapies. The acquisition includes EsoBiotec’s Engineered NanoBody Lentiviral (ENaBL) platform, which empowers the […]

Belgium: AstraZeneca advances cell therapy ambition with US$1bn acquisition of EsoBiotec

March 18, 2025

IVD – Tools Life Sciences M&A News AstraZeneca

Asker Healthcare, a Sweden-based provider of medical products and solutions, has set the final price in its upcoming IPO at SEK70 per share, equivalent to a valuation of approximately SEK26.8bn. The […]

Sweden: Asker sets final price for IPO

March 18, 2025

Life Sciences Medtech – Hospital Equipment Medtech – Medical Devices and Implants News Public Equity

Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has held the final close of Sofinnova Biovelocita II, a biotech acceleration fund. Biovelocita II […]

France: Sofinnova Partners exceeds target with close of €165m biotech acceleration fund

March 18, 2025

Manufacturing – Specialty Pharma News Pharma Venture Alex Leech

Our Sectors

We are experts at what we do

Healthcare

Social Care

Biopharmaceuticals

Medical Technologies

Enabling Services

01 Our People

A dedicated team of executive search experts, delivering for you

The Compass Carter Osborne team are healthcare and life science experts. As a trusted advisor we bring decades of search experience and an unparalleled track record of delivery across our dedicated sectors for our investor clients – relied upon time and again to build outstanding leadership teams.

Familiar faces at key industry events, our expertise extends beyond the mere placing of people with our consultants bringing together sector leaders to address key challenges, working in partnership to produce tangible solutions.

Our Team

Meet the Team

Adam Carter

Meet the Team

Luke Osborne

Meet the Team

Sam Leighton-Smith BA Hons

02 Expertise

Unearthing rare talent, that drive successful exits

Responsive, adaptable, and emotionally intelligent, Compass Carter Osborne avoid the one-size-fits-all approach to ensure our clients achieve their desired outcome by presenting a broad range of intuitive, tailored solutions, based on specific needs.

Expertise

Board

Expertise

Executive Leadership

Expertise

Finance & Commercial

Expertise

Corporate Services

03 Our Approach

Tailoring our offering,
to provide a bespoke service

Results driven, not process led, CCO avoid the conformity of a rigid process. Never assumptive, we listen and adopt an agreed approach which most closely delivers to a clients specific needs. Understanding the uniqueness of each role, our people tailor a search to bespoke requirements to ensure solutions that delivers the best possible results first time, every time.

Our Approach

A trusted advisor to the investment community
providing leaders advancing the healthcare and life sciences sectors

What our clients say

“Compass Carter Osborne really delivered for us in our search for a new CEO for Outcomes First Group. It was a vitally important assignment given that we were recruiting a successor for a long standing and highly successful CEO in a sector-leading business. Compass Carter Osborne went above and beyond in developing a deep understanding of the business and our requirements, and in only presenting candidates that closely met these. They think very creatively and their focus was very sharp; they particularly understood the culture of the business. The search was speedy and well organised, with a very high standard of verbal and written feedback. They have a granular knowledge of the sector and because of the way in which they work, we were fully involved throughout and achieved a great result. A really excellent search – thank you.”

Outcomes First Group – Chair

“Compass Carter Osborne started from the very beginning with a detailed, professional explanation of the available position. They spent time to present the great opportunity and chance to accelerate my career but at the same time, the challenge, and the strong expectation from their client.”

Hengrui Therapeutics – VP, Head Biological Drug Discovery

“Compass Carter Osborne delivered on a key appointment for the PFA and the wider football industry. It was a complex brief involving creating an entirely new position. The role was vitally important, with the successful candidate taking on a sensitive and multifaceted responsibility across CTE, concussion and brain health in professional football. CCO led a comprehensive and exhaustive process, developing a deep understanding of the union’s requirements and using his expert knowledge to help scope and evolve the brief throughout the search. The entire process was professional, efficient and well organised, with consistent communication and feedback at every stage.”

The Professional Footballers Association (PFA) – Chief Executive Officer

“I have been so impressed by Luke’s integrity, clear purpose and drive to achieve for his clients. Luke has worked with Priory on a number of things but more recently to source two independent Non Executive Directors and a Director of Talent Acquisition. He has kept us informed, fielded some great candidates and follows up at each stage, even when they have started. I would really recommend him if you are searching for high calibre individuals.”

Priory Group – Chief Executive Officer

“I recently had the pleasure of being appointed to an independent healthcare provider as a NED after being put forward for the role by Luke. Throughout the whole recruitment process I was treated with respect and felt valued. I was particularly impressed with the follow up support after the decision to appoint me, which I have never experienced from other search companies. Luke continued to check in with me to ensure my onboarding went smoothly and that I had settled into the role. Overall, a highly professional and comprehensive approach delivered personally by Luke.”

Priory – Independent Non-Executive Director

“Luke was absolutely brilliant along the journey. He acted as a real partner and was able to answer to all my questions in order to get comfortable with the decision of making the change. His expertise and knowledge of the sector really came out along the process. Most importantly, he was always available when I needed him to be, which is something I valued a lot. In summary, I couldn’t recommend him and Compass Carter Osborne enough.”

AniCura – Group Chief Operating Officer

“We worked with Compass Carter Osborne in the search for our Chief Financial Officer and from the start it was clear they were a good choice of partner. A focus on understanding our needs as a business, and mine personally as a CEO were front of mind for Paul and Kieran. They took the time to listen, understand and not only focus on the functional aspects of the role – but critically, the team fit and culture we are building. Process, structure and follow-through were like clockwork, and the quality of candidates were of a consistently high-level. I would highly recommend Compass Carter Osborne.”

Renaiss Health – Chief Executive Officer

“I’ve known Tarquin for over 15 years, during which time he has delivered a number of executive assignments at senior level, including COO/executive team and senior management roles in scientific/professional disciplines (his network in the biotech/life-sciences sector is second-to-none!). He works hard to truly understand both the candidate brief and the culture of the company, sets realistic expectations and retains regular contact as an assignment progresses, always providing thorough updates and pragmatic advice. He has the highest levels of professionalism and integrity – he really is a pleasure to work with.”

One Nucleus – Director

“Jamie did a great job – he really took the time to understand our business, our needs and what we were looking for. We knew our brief was specific, yet Jamie met all our expectations with the search. He maintained a high standard of communication and meticulous attention to detail throughout the process. I would recommend Jamie and the Compass Carter Osborne team without hesitation.”

Melrose Education – Chair & CEO

“Our recent work with Compass Carter Osborne was exceptional. The search was perfectly organised, response times were swift, and due to the consultant market knowledge and network, we quickly found our ideal candidate.”

Schoen Clinic – Member of Group Executive